Jiaying Lin

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Jian Su, Qing Zhou, Hai-Yan Tu, 2016, Clinical Cancer Research.

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2010, Molecular Cancer.

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.

Yi-long Wu, Jin-Ji Yang, Jie Huang, 2021, Clinical lung cancer.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Network Boston.

Open Access RESEARCH

Young Yang, Peter Suber, Yi-long Wu, 2010 .

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Jin-Ji Yang, W. Zhong, K. Yin, 2023, Molecular oncology.